Fortacin
Procedural steps taken and scientific information after the authorisation
Application 
Scope
number
Opinion/ 
Commission 
Product 
Summary
Notification1 
Decision 
Information 
issued on
Issued2 / 
affected3 
amended 
on
R/0038
Renewal of the marketing authorisation.
20/07/2023
15/09/2023
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL
the CHMP considered that the benefit-risk balance of 
Fortacin in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity.
IAIN/0037
B.III.1.a.3 - Submission of a new/updated or 
21/02/2023
n/a
deletion of Ph. Eur. Certificate of Suitability to the 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures.
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us 
Send us a question  Go to www.ema.europa.eu/contact  Telephone +31 (0)88 781 6000
An agency of the European Union
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition)
PSUSA/10110
Periodic Safety Update EU Single assessment - 
12/01/2023
n/a
PRAC Recommendation - maintenance
/202205
lidocaine / prilocaine (centrally authorised product 
only)
II/0035/G
This was an application for a group of variations.
15/09/2022
15/09/2023
Annex II and 
The manufacturing site Genetic S.p.A., Via Canfora, 64, 
B.IV.1.c - Change of a measuring or administration 
device - Addition or replacement of a device which is 
an integrated part of the primary packaging
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
PL
84084 Fisciano (SA), Italy is added in Annex IIA as a 
manufacturer responsible for batch release.
Page 2/10
Including batch control/testing
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process
IA/0034/G
This was an application for a group of variations.
13/04/2022
n/a
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer
IA/0033
A.7 - Administrative change - Deletion of 
27/07/2021
08/07/2022
Annex II and 
manufacturing sites
PL
IA/0032
B.II.e.4.a - Change in shape or dimensions of the 
25/09/2020
n/a
container or closure (immediate packaging) - Non-
sterile medicinal products
II/0030
Change in the legal status of Fortacin from ‘medicinal 
23/07/2020
27/08/2020
SmPC, Annex 
Please refer to Scientific Discussion ‘Fortacin-H-C-2693-II-
product subject to medical prescription’ to ‘medicinal 
II, Labelling 
0030’. For more information, please refer to the Summary 
product not subject to medical prescription’. As a 
and PL
of Product Characteristics.
consequence, sections 4.4, 4.8, 4.9 of the SmPC are 
updated. The package leaflet and labelling are 
updated accordingly. Furthermore, the product 
information is being brought in line with the latest 
QRD template (version 10.1). The RMP is updated to 
Page 3/10
version 4.0.
C.I.5.b - Change in the legal status of a medicinal 
product for centrally authorised products - All other 
legal status changes
IA/0031
B.II.b.2.a - Change to importer, batch release 
16/12/2019
n/a
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place
PSUSA/10110
Periodic Safety Update EU Single assessment - 
28/11/2019
n/a
PRAC Recommendation - maintenance
/201905
lidocaine / prilocaine (centrally authorised product 
only)
IAIN/0029
B.II.b.2.c.1 - Change to importer, batch release 
02/10/2019
n/a
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing
IAIN/0027/G
This was an application for a group of variations.
11/03/2019
09/03/2020
Annex II and 
PL
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing
Page 4/10
PSUSA/10110
Periodic Safety Update EU Single assessment - 
29/11/2018
n/a
PRAC Recommendation - maintenance
/201805
lidocaine / prilocaine (centrally authorised product 
only)
IB/0026
B.II.b.5.z - Change to in-process tests or limits 
06/11/2018
n/a
applied during the manufacture of the finished 
product - Other variation
R/0023
Renewal of the marketing authorisation.
26/07/2018
17/09/2018
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL
Fortacin in the approved indication remains favourable, but 
recommended that one additional five-year renewal be 
required based on the following pharmacovigilance 
grounds:
Limited safety information is available because of limited 
exposure, due to recent marketing and the limited 
marketing of the medicinal product.
IA/0025
B.II.e.4.a - Change in shape or dimensions of the 
29/08/2018
n/a
container or closure (immediate packaging) - Non-
sterile medicinal products
IA/0022
A.7 - Administrative change - Deletion of 
15/02/2018
17/09/2018
Annex II and 
manufacturing sites
PL
IB/0020
C.I.11.z - Introduction of, or change(s) to, the 
02/02/2018
n/a
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation
IA/0021/G
This was an application for a group of variations.
24/01/2018
n/a
Page 5/10
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test
PSUSA/10110
Periodic Safety Update EU Single assessment - 
30/11/2017
n/a
PRAC Recommendation - maintenance
/201705
lidocaine / prilocaine (centrally authorised product 
only)
T/0019
Transfer of Marketing Authorisation
11/10/2017
30/10/2017
SmPC, 
Labelling and 
PL
IB/0017/G
This was an application for a group of variations.
27/06/2017
n/a
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation
PSUSA/10110
Periodic Safety Update EU Single assessment - 
09/06/2017
n/a
PRAC Recommendation - maintenance
/201611
lidocaine / prilocaine (centrally authorised product 
only)
II/0015
B.II.d.1.e - Change in the specification parameters 
23/03/2017
n/a
and/or limits of the finished product - Change 
outside the approved specifications limits range
Page 6/10
N/0014
Minor change in labelling or package leaflet not 
18/01/2017
17/03/2017
Labelling
connected with the SPC (Art. 61.3 Notification)
PSUSA/10110
Periodic Safety Update EU Single assessment - 
01/12/2016
n/a
PRAC Recommendation - maintenance
/201605
lidocaine / prilocaine (centrally authorised product 
only)
N/0013
Update of the package leaflet to include the list of 
08/08/2016
17/03/2017
PL
local representatives.
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification)
PSUSA/10110
Periodic Safety Update EU Single assessment - 
09/06/2016
n/a
PRAC Recommendation - maintenance
/201511
lidocaine / prilocaine (centrally authorised product 
only)
IB/0011/G
This was an application for a group of variations.
17/05/2016
17/03/2017
SmPC, Annex 
II, Labelling 
and PL
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products
B.II.b.2.a - Change to importer, batch release 
Page 7/10
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process
B.II.e.5.d - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
nonparenteral multi-dose (or single-dose, partial 
use) products
IAIN/0010/G
This was an application for a group of variations.
19/04/2016
17/03/2017
Annex II and 
PL
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
Page 8/10
new manufacturer (replacement or addition)
PSUSA/10110
Periodic Safety Update EU Single assessment - 
03/12/2015
n/a
PRAC Recommendation - maintenance
/201505
lidocaine / prilocaine (centrally authorised product 
only)
PSUSA/10110
Periodic Safety Update EU Single assessment - 
11/06/2015
n/a
PRAC Recommendation - maintenance
/201411
lidocaine / prilocaine (centrally authorised product 
only)
IA/0007
B.III.1.a.2 - Submission of a new/updated or 
27/03/2015
n/a
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer
IA/0006
B.III.1.a.2 - Submission of a new/updated or 
27/03/2015
n/a
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer
IB/0005
C.I.z - Changes (Safety/Efficacy) of Human and 
20/03/2015
n/a
Veterinary Medicinal Products - Other variation
PSUV/0001
Periodic Safety Update
04/12/2014
IAIN/0003
C.I.8.a - Introduction of or changes to a summary of 
28/11/2014
n/a
n/a
PRAC Recommendation - maintenance
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location
IAIN/0002/G
This was an application for a group of variations.
26/09/2014
15/10/2015
SmPC, 
Page 9/10
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition)
Labelling and 
PL
Page 10/10
